



# STIC Search Report

## Biotech-Chem Library

Database Tracking Number: 118416

ybille Delacroix  
on: rem 4c85 &4c70  
nit: 1614  
day, April 01, 2004

Serial Number: 09/676032

**From: Mary Hale**  
**Location: Biotech/Chem Library**  
**Rem 1D86**  
**Phone: 2-2507**

**Mary.Hale@uspto.gov**

Search Notes

hed-

and usage

Feel free to contact me if you  
have any questions.

## SEARCH REQUEST FORM

Requestor's Name: C. DELACROIX Serial Number: 09/676,032  
Date: 3-31-04 Phone: 272-0572 <sup>571</sup> Art Unit: 1614

Rm: 4C85 <sup>1614</sup> Box 4C70

**Search Topic:**

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Please search the attached  
Compounds & Compositions Therein.  
Thanks

CM

Rush Search

Approved

920  
9/10

Please  
rush!

TK Rye

SPC, No 1615

Thanks  
CM

Argon  
Quanta  
Carbon

### STAFF USE ONLY


Date completed: 4/1  
Searcher: Staub  
Terminal time: \_\_\_\_\_  
Elapsed time: \_\_\_\_\_  
CPU time: \_\_\_\_\_  
Total time: 10  
Number of Searches: \_\_\_\_\_  
Number of Databases: \_\_\_\_\_

Search Site	Vendors
<input type="checkbox"/> STIC	<input type="checkbox"/> IG
<input type="checkbox"/> CM-1	<input type="checkbox"/> STN
<input type="checkbox"/> Pre-S	<input type="checkbox"/> Dialog
Type of Search	
<input type="checkbox"/> N.A. Sequence	<input type="checkbox"/> APS
<input type="checkbox"/> A.A. Sequence	<input type="checkbox"/> Geninfo
<input type="checkbox"/> Structure	<input type="checkbox"/> SDC
<input type="checkbox"/> Bibliographic	<input type="checkbox"/> DARC/Questel
	<input type="checkbox"/> Other

O : Delacoux  
676032

d 13 que stat; fil medl, hcapl, biosis, embase; s 13 and (cancer? or carcino? or  
mour or tumor or melanoma)

STR



ODE ATTRIBUTES:

FAULT MLEVEL IS ATOM

FAULT ECLEVEL IS LIMITED

APH ATTRIBUTES:

NG(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 16

EREO ATTRIBUTES: NONE

133 SEA FILE=REGISTRY SSS FUL L1

0.0% PROCESSED 489 ITERATIONS

133 ANSWERS

SEARCH TIME: 00.00.02

OST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

ULL ESTIMATED COST

SESSION

157.31

LE 'MEDLINE' ENTERED AT 09:15:10 ON 01 APR 2004

LE 'HCAPLUS' ENTERED AT 09:15:10 ON 01 APR 2004

SE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

LEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

LE 'BIOSIS' ENTERED AT 09:15:10 ON 01 APR 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

LE 'EMBASE' ENTERED AT 09:15:10 ON 01 APR 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

4 0 FILE MEDLINE  
5 7 FILE HCAPLUS  
6 0 FILE BIOSIS  
7 0 FILE EMBASE


TOTAL FOR ALL FILES

3 7 L3 AND (CANCER? OR CARCINO? OR TUMOUR OR TUMOR OR MELANOMA)

> d 1-7 cbib abs hitstr

searched by: Mary Hale 571-272-2507 REM 1D86

02:889200 Document No. 137:370090 Preparation of benzimidazolecarbamates for treatment of **cancer** or viral infections. Quada, James C., Jr.; Agyin, Joseph K.; Camden, James Berger (The Procter & Gamble Company, USA). U.S. US 6482843 B1 20021119, 20 pp., Cont.-in-part of U.S. Ser. No. 857,811. (English). CODEN: USXXAM. APPLICATION: US 2000-676407 20000929. PRIORITY: US 1997-857811 19970516.



3 Title compds., e.g. [I; R = O<sub>2</sub>CR<sub>1</sub>; R<sub>1</sub> = alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkyl, (substituted) Ph, PhNH, PhCH<sub>2</sub>, etc.], were prepared. Thus, Me 2-amino-5-hydroxybenzimidazole carbamate and 3,5,5-trimethylhexanoyl chloride were stirred in THF at 23-40° to give I (R = O<sub>2</sub>CCH<sub>2</sub>CHMeCH<sub>2</sub>CMe<sub>3</sub>). The latter inhibited human colon **carcinoma** with IC<sub>50</sub> = 15.8 μM.

F 216148-85-5P 436810-09-2P 436810-11-6P


436810-15-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolecarbamates for treatment of **cancer** or viral infections)


N 216148-85-5 HCPLUS

N 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




N 436810-09-2 HCPLUS

N 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




N 436810-11-6 HCPLUS

N 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-15-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)



IT 135696-76-3 135696-78-5 216148-83-3

216148-87-7 216148-89-9 216148-90-2

436810-08-1 436810-10-5 436810-12-7

436810-13-8 436810-14-9 436810-16-1

436810-17-2 436810-18-3 436810-19-4

436810-20-7 436810-21-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(preparation of benzimidazolecarbamates for treatment of **cancer** or viral infections)


RN 135696-76-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 216148-90-2 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-chloropropyl ester (9CI) (CA INDEX NAME)




RN 436810-13-8 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)



RN 436810-14-9 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-16-1 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-18-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-20-7 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)



RN 436810-21-8 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN  
2002:551611 Document No. 137:109276 Preparation of methyl 1H-benzimidazole-2-carbamates for treating **cancer** or viral infections. Camden, James Berger; Agyin, Joseph K.; Quada, James C., Jr. (The Procter & Gamble Company, USA). U.S. US 6423736 B1 20020723, 19 pp., Cont. of U.S. Ser. No. 857,811, (English). CODEN: USXXAM. APPLICATION: US 2000-676409 20000929. PRIORITY: US 1997-857811 19970516.

GI




AB The title compds. [I (R = OCORa; Ra = (un)substituted Ph), II (R = CONR1R2, CO2R1, OCOR1, NHCOR1; R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2 = H, alkyl)] were prepared. Thus, reacting Me 2-amino-5-hydroxybenzimidazole carbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOC2CHMeCH2CMe3] which showed IC50 of 20.1  $\mu$ M and IC50 of 15.8  $\mu$ M for growth inhibition of B16 murine **melanoma** cells and H29 human colon **cancer** cells, resp. Such compds. I may be used in combination with a chemotherapeutic agent and/or a potentiator.

IT 135696-76-3P 135696-78-5P 216148-83-3P  
216148-85-5P 216148-87-7P 216148-89-9P  
216148-90-2P 436810-08-1P 436810-09-2P  
436810-10-5P 436810-11-6P 436810-12-7P  
436810-13-8P 436810-14-9P 436810-15-0P  
436810-16-1P 436810-17-2P 436810-18-3P  
436810-19-4P 436810-20-7P 436810-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of Me benzimidazole-2-carbamates for treating **cancer** or viral infections)

RN 135696-76-3 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 216148-87-7 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)



RN 216148-89-9 HCPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 216148-90-2 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-09-2 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-11-6 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-chloropropyl ester (9CI) (CA INDEX NAME)



RN 436810-13-8 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)




RN 436810-14-9 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 5-hydroxypentyl ester (9CI) (CA INDEX NAME)



RN 436810-15-0 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-16-1 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-18-3 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-20-7 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)




RN 436810-21-8 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN  
 2002:551610 Document No. 137:109275 Preparation of methyl 1H-benzimidazole-2-carbamates for treating **cancer** or viral infections. Camden, James Berger; Quada, James C., Jr.; Agyin, Joseph K. (The Procter & Gamble Company, USA). U.S. US 6423735 B1 20020723, 17 pp., Cont. of U.S. Ser. No. 857,811. (English). CODEN: USXXAM. APPLICATION: US 2000-676029 20000929. PRIORITY: US 1997-857811 19970516.

GI



AB The title compds. [I (R = OCORa; Ra = (un)substituted Ph), II (R = CONR1R2, CO2R1, OCOR1, NHCOR1; R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2 = H, alkyl)] were prepared. Thus, reacting Me 2-amino-5-hydroxybenzimidazole carbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOCH2CHMeCH2CMe3] which showed IC50 of 20.1  $\mu$ M and IC50 of 15.8  $\mu$ M for growth inhibition of B16 murine **melanoma** cells and H29 human colon **cancer** cells, resp. Such compds. I

may be used in combination with a chemotherapeutic agent and/or a potentiator such as DNA-interactive agent, an antimetabolite, a tubulin-interactive agent, a hormonal agent, an antihormonal antigen, and an adrenal corticosteroid.


IT 135696-76-3P 135696-78-5P 216148-83-3P  
216148-85-5P 216148-87-7P 216148-89-9P  
216148-90-2P 436810-08-1P 436810-09-2P  
436810-10-5P 436810-11-6P 436810-12-7P  
436810-13-8P 436810-14-9P 436810-15-0P  
436810-16-1P 436810-17-2P 436810-18-3P  
436810-19-4P 436810-20-7P 436810-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Me benzimidazole-2-carbamates for treating **cancer** or viral infections)


RN 135696-76-3 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)



RN 216148-90-2 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-09-2 HCPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-, 2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-11-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-, 3-chloropropyl ester (9CI) (CA INDEX NAME)




RN 436810-13-8 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-, 4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)




RN 436810-14-9 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-15-0 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-16-1 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-18-3 HCPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-20-7 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)




RN 436810-21-8 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 7 HCPLUS COPYRIGHT 2004 ACS on STN  
2002:534039 Document No. 137:93753 Preparation of 2,5-disubstituted benzimidazoles used in the treatment of **cancer** or viral infections. Camden, James Berger; Agyin, Joseph K.; Quada, James C., Jr. (The Procter & Gamble Company, USA). U.S. US 6420411 B1 20020716, 18 pp., Cont.-in-part of U. S. Ser. No. 857,811. (English). CODEN: USXXAM.  
APPLICATION: US 2000-676202 20000929. PRIORITY: US 1997-857811 19970516.

GI




AB Title compds. I [R1 = (halo)alkyl, hydroxyalkyl, (halo)alkenyl, cycloalkyl, heterocycloalkyl, substituted Ph and analogs thereof] were prepared. For instance, Me 5-amino-1H-benzimidazol-2-ylcarbamate was acylated with 3,5,5-trimethylhexanoyl chloride to provide I (R1 = CH<sub>2</sub>CH(CH<sub>3</sub>)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; II). II had IC<sub>50</sub> = 6.6 and 7.0  $\mu$ M for the murine melanoma and human colon carcinoma cell line resp. I are used for the treatment of cancers or viral infections and may be used in combination with a chemotherapeutic agent and/or a potentiator.

IT 135696-76-3P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester 135696-78-5P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester 216148-83-3P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester 216148-85-5P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester 216148-87-7P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester 216148-89-9P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester 216148-90-2P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester 436810-08-1P 436810-09-2P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-hydroxyethoxy)ethyl ester 436810-10-5P 436810-11-6P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(dimethylamino)ethyl ester 436810-12-7P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-chloropropyl ester 436810-13-8P 436810-14-9P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 5-hydroxypentyl ester 436810-15-0P 436810-16-1P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2,3,3,3-pentafluoropropyl ester 436810-17-2P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-fluoro-1-(fluoromethyl)ethyl ester 436810-18-3P 436810-19-4P 436810-20-7P 436810-21-8P, 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,7-dimethyl-6-octenyl ester


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug; preparation of substituted benzimidazole-2-carbamates as antiviral/antitumor agents)

RN 135696-76-3 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 216148-90-2 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-09-2 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-10-5 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 phenylmethyl ester (9CI) (CA INDEX NAME)



RN 436810-11-6 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-chloropropyl ester (9CI) (CA INDEX NAME)




RN 436810-13-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)




RN 436810-14-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-15-0 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-16-1 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)




RN 436810-17-2 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-18-3 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 436810-19-4 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-20-7 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)




RN 436810-21-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN  
2002:461292 Document No. 137:33301 Preparation of 2,5-disubstituted benzimidazoles used in the treatment of **cancer** or viral infections. Quada, James C., Jr.; Agyin, Joseph K.; Camden, James Berger (The Procter & Gamble Company, USA). U.S. US 6407131 B1 20020618, 18 pp., Cont.-in-part of U.S. Ser. No. 857,811. (English). CODEN: USXXAM.  
APPLICATION: US 2000-676030 20000929. PRIORITY: US 1997-857811 19970516.

GI



AB Title compds. I [R1 = (halo)alkyl, hydroxyalkyl, (halo)alkenyl, cycloalkyl, heterocycloalkyl, substituted Ph and analogs thereof] were prepared For instance, Me 2-amino-5-hydroxybenzimidazole carbamate was acylated with 3,5,5-trimethylhexanoyl chloride to provide I (R1 = CH2CH2CH(CH3)CH2C(CH3)3; II). II had IC50 = 20.1 and 15.8  $\mu$ M for the murine **melanoma** and human colon **carcinoma** cell line resp. I are used for the treatment of **cancers** or viral infections and may be used in combination with a chemotherapeutic agent and/or a potentiator.

IT 135696-76-3P 135696-78-5P 216148-83-3P  
216148-85-5P 216148-87-7P 216148-89-9P  
216148-90-2P 436810-08-1P 436810-09-2P  
436810-10-5P 436810-11-6P 436810-12-7P  
436810-13-8P 436810-14-9P 436810-15-0P  
436810-16-1P 436810-17-2P 436810-18-3P  
436810-19-4P 436810-20-7P 436810-21-8P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(drug; preparation of substituted benzimidazole-2-carbamates as antiviral/antitumor agents)


RN 135696-76-3 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)




RN 216148-83-3 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 216148-90-2 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 436810-08-1 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-chloroethoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-09-2 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-hydroxyethoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 436810-10-5 HCPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 436810-11-6 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-12-7 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-chloropropyl ester (9CI) (CA INDEX NAME)




RN 436810-13-8 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-hydroxy-2-butenyl ester (9CI) (CA INDEX NAME)




RN 436810-14-9 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 5-hydroxypentyl ester (9CI) (CA INDEX NAME)




RN 436810-15-0 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-chloro-1-(chloromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-16-1 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2,2,3,3,3-pentafluoropropyl ester (9CI) (CA INDEX NAME)



RN 436810-17-2 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-fluoro-1-(fluoromethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-18-3 HCAPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-fluoroethyl ester (9CI) (CA INDEX NAME)



RN 436810-19-4 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-bromo-1-(bromomethyl)ethyl ester (9CI) (CA INDEX NAME)




RN 436810-20-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)



RN 436810-21-8 HCAPLUS



CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,7-dimethyl-6-octenyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:408648 Document No. 137:6176 Preparation of aromatic acid derivatives useful as serine protease inhibitors. Bisacchi, Gregory S.; Sutton, James C., Jr.; Slusarchyk, William A.; Treuner, Uwe D.; Zhao, Guohua; Cheney, Daniel L.; Wu, Shung C.; Shi, Yan (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 2002042273 A2 20020530, 182 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US46884 20011107. PRIORITY: US 2000-PV246392 20001107.

GI




AB Aromatic compds. I, are useful as serine protease inhibitors, wherein ring B is Ph or pyridyl; W is amide, alkyl, alkenyl, heterocycle, heteroaryl, aryl, cycloalkyl; L is a linker group; X is N, CH, or C, provided that X is C when R1 and R2 join to form a fully unsatd. ring; Z is an optionally-substituted monocyclic or bicyclic ring system; R is H, alkoxy, amine, alkyl, alkenyl, halogen, haloalkyl, cyano, nitro, alkylthio, CHO, acyl, CO2H, alkoxy carbonyl, sulfonamido, sulfonyl, Ph; R1 and R2 (i) are independently selected from hydrogen, alkyl, alkenyl, heteroaryl, aryl, heterocycle, and cycloalkyl; or (ii) are taken together to form an aryl, heteroaryl, cycloalkyl, or heterocycle, provided that R1 and R2 do not together form pyrazole when W is methoxy and Z is biphenyl; and when R1 and R2 individually or together form a heteroaryl, aryl, heterocycle, cycloalkyl; R3 is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocycle, cycloalkyl, or alkyl substituted with -OC(O)R4 or -OC(O)OR4, wherein R4 is alkyl, cycloalkyl, provided that R3 is not Ph when W is methoxy. Thus, II was prepared for treating a coagulation-associated disorder, an inflammatory or immune disease, or metastases (no data). Included within the scope of the invention are pharmaceutical compns. for treating a serine protease disease, an inflammatory or immune condition, or cancer.

IT 218301-15-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of aromatic acid derivs. useful as anti-inflammatory, anticoagulant, antitumor, immunomodulator agents and serine protease inhibitors)


RN 218301-15-6 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 7 HCPLUS COPYRIGHT 2004 ACS on STN  
 1998:764283 Document No. 130:20597 Benzimidazole-2-carbamates for the treatment of viral infections and **cancer**. Camden, James Berger (The Procter & Gamble Company, USA). PCT Int. Appl. WO 9851304 A1 19981119, 24 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.  
 APPLICATION: WO 1997-US21565 19971126. PRIORITY: US 1997-857811 19970516.

GI



I

AB A pharmaceutical composition that is effective in the treatment of HIV and other viral infections and inhibits growth of **cancers** and **tumors** in mammals comprises a benzimidazole derivative (I; R = H, CO<sub>2</sub>H, OH, NH<sub>2</sub>, CO<sub>2</sub>R<sub>1</sub>; R<sub>1</sub> = alkoxy, haloalkyl, alkenyl, cycloalkyl), the pharmaceutically acceptable salts thereof, or mixts. thereof. I (R = H) inhibits the growth of B16 murine **melanoma** and HT29 human colon **carcinoma** cells with IC<sub>50</sub> of 4.925 and 3.297  $\mu$ M, resp.

IT 216148-83-3 216148-85-5 216148-87-7


216148-88-8 216148-89-9 216148-90-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(benzimidazole-2-carbamates for treatment of **cancer** and viral infections)

RN 216148-83-3 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)



RN 216148-85-5 HCPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)




RN 216148-87-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)




RN 216148-88-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester (9CI) (CA INDEX NAME)




RN 216148-89-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)



RN 216148-90-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




IT 216148-91-3 216148-94-6 216148-95-7  
 216148-96-8 216148-98-0 216149-00-7  
 216149-02-9 216149-09-6 216149-10-9  
 216149-11-0 216149-13-2 216149-14-3  
 216149-16-5 216149-17-6 216149-18-7  
 216149-19-8 216149-20-1 216149-21-2  
 216149-22-3 216149-23-4 216149-27-8  
 216149-29-0 216149-31-4 216149-33-6  
 216149-35-8 216149-37-0 216149-43-8  
 216149-45-0 216149-47-2 216149-53-0  
 216149-56-3 216149-59-6 216149-62-1  
 216149-69-8 216149-72-3 216149-74-5  
 216149-77-8 216149-81-4 216149-84-7  
 216149-85-8 216149-87-0 216149-88-1  
 216149-91-6 216149-92-7 216149-95-0  
 216149-96-1 216149-98-3 216149-99-4  
 216150-01-5 216150-02-6 216150-03-7  
 216150-04-8 216150-06-0 216150-07-1  
 216150-08-2 216150-09-3 216150-10-6  
 216150-12-8 216150-17-3 216150-19-5  
 216150-20-8 216150-21-9 216150-22-0  
 216150-23-1 216150-27-5 216150-28-6  
 216150-30-0 216150-31-1 216150-32-2  
 216150-34-4 216150-35-5 216150-40-2  
 216150-41-3 216150-42-4 216150-43-5  
 216150-44-6 216150-45-7 216150-46-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(benzimidazole-2-carbamates for treatment of **cancer** and viral infections)

RN 216148-91-3 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216148-94-6 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216148-95-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216148-96-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-83-3

CMF C14 H16 Cl N3 O4



CM 2


CRN 7697-37-2  
CMF H N O3



RN 216148-98-0 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, phosphate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-83-3  
CMF C14 H16 Cl N3 O4



CM 2


CRN 7664-38-2  
CMF H3 O4 P



RN 216149-00-7 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3  
CMF C14 H16 Cl N3 O4



CM 2


CRN 64-18-6  
CMF C H2 O2

O=CH-OH

RN 216149-02-9 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
4-chlorobutyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX  
NAME)

CM 1


CRN 216148-83-3  
CMF C14 H16 Cl N3 O4



CM 2

CRN 87-69-4  
CMF C4 H6 O6


Absolute stereochemistry.



RN 216149-09-6 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
4-chlorobutyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-83-3  
CMF C14 H16 Cl N3 O4



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 216149-10-9 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-83-3  
CMF C14 H16 Cl N3 O4



CM 2

CRN 77-92-9  
CMF C6 H8 O7




RN 216149-11-0 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-83-3  
CMF C14 H16 Cl N3 O4



CM 2


CRN 65-85-0  
CMF C7 H6 O2



RN 216149-13-2 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)


CM 1

CRN 216148-83-3  
CMF C14 H16 Cl N3 O4



CM 2

CRN 69-72-7  
CMF C7 H6 O3




RN 216149-14-3 HCAPLUS  
CN L-Ascorbic acid, compd. with 4-chlorobutyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 50-81-7  
CMF C6 H8 O6


Absolute stereochemistry.



RN 216149-16-5 HCPLUS  
CN Butanedioic acid, hydroxy-, compd. with 4-chlorobutyl 2-[ (methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-83-3  
CMF C14 H16 Cl N3 O4



CM 2


CRN 6915-15-7  
CMF C4 H6 O5



RN 216149-17-6 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-,

Searched by: Mary Hale 571-272-2507 REM 1D86


2-(2-ethoxyethoxy)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216149-18-7 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216149-19-8 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5


CMF C16 H21 N3 O6



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216149-20-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5


CMF C16 H21 N3 O6



CM 2

CRN 7697-37-2

CMF H N O3




RN 216149-21-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5


CMF C16 H21 N3 O6



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 216149-22-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5

CMF C16 H21 N3 O6



CM 2

CRN 64-18-6

CMF C H2 O2




RN 216149-23-4 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5

CMF C16 H21 N3 O6




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.


Searched by: Mary Hale 571-272-2507 REM 1D86



RN 216149-27-8 HCPLUS  
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
 2-(2-ethoxyethoxy)ethyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-85-5  
 CMF C16 H21 N3 O6



CM 2

CRN 110-16-7  
 CMF C4 H4 O4


Double bond geometry as shown.



RN 216149-29-0 HCPLUS  
 CN Butanedioic acid, hydroxy-, compd. with 2-(2-ethoxyethoxy)ethyl  
 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX  
 NAME)

CM 1


CRN 216148-85-5  
 CMF C16 H21 N3 O6



CM 2

Searched by: Mary Hale 571-272-2507 REM 1D86


CRN 6915-15-7  
CMF C4 H6 O5



RN 216149-31-4 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-85-5  
CMF C16 H21 N3 O6



CM 2


CRN 77-92-9  
CMF C6 H8 O7



RN 216149-33-6 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-85-5  
CMF C16 H21 N3 O6



CM 2


CRN 65-85-0  
CMF C7 H6 O2



RN 216149-35-8 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-,  
2-(2-ethoxyethoxy)ethyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX  
NAME)


CM 1

CRN 216148-85-5  
CMF C16 H21 N3 O6



CM 2


CRN 69-72-7  
CMF C7 H6 O3



RN 216149-37-0 HCPLUS  
CN L-Ascorbic acid, compd. with 2-(2-ethoxyethoxy)ethyl 2-  
[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX  
NAME)

CM 1


CRN 216148-85-5  
CMF C16 H21 N3 O6




CM 2

CRN 50-81-7  
CMF C6 H8 O6

Absolute stereochemistry.




RN 216149-43-8 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monohydrochloride (9CI) (CA. INDEX NAME)



● HCl

RN 216149-45-0 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216149-47-2 HCPLUS

Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-87-7  
CMF C14 H15 N3 O4



CM 2

CRN 7664-93-9  
CMF H2 O4 S




RN 216149-53-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7  
CMF C14 H15 N3 O4



CM 2

CRN 7697-37-2  
CMF H N O3



RN 216149-56-3 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 216149-59-6 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7

CMF C14 H15 N3 O4



CM 2

CRN 64-18-6

CMF C H2 O2




RN 216149-62-1 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

Searched by: Mary Hale 571-272-2507 REM 1D86

CM 1


CRN 216148-87-7  
CMF C14 H15 N3 O4



CM 2

CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.




RN 216149-69-8 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butene-1,4-dioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-87-7  
CMF C14 H15 N3 O4



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 216149-72-3 HCAPLUS

CN Butanedioic acid, hydroxy-, compd. with 3-butenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 216149-74-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 216149-77-8 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-but enyl ester, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 65-85-0

CMF C7 H6 O2




RN 216149-81-4 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-but enyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)

CM 1


CRN 216148-87-7

CMF C14 H15 N3 O4



CM 2


CRN 69-72-7  
CMF C7 H6 O3



RN 216149-84-7 HCAPLUS  
CN L-Ascorbic acid, compd. with 3-butenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-87-7  
CMF C14 H15 N3 O4




CM 2

CRN 50-81-7  
CMF C6 H8 O6

Absolute stereochemistry.




RN 216149-85-8 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216149-87-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
3,3,7-trimethyl-6-octenyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216149-88-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
3,3,7-trimethyl-6-octenyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216149-91-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,  
3,3,7-trimethyl-6-octenyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-88-8

CMF C21 H29 N3 O4



CM 2


CRN 7697-37-2  
CMF H N O3



RN 216149-92-7 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, phosphate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-88-8  
CMF C21 H29 N3 O4



CM 2


CRN 7664-38-2  
CMF H3 O4 P



RN 216149-95-0 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-88-8  
CMF C21 H29 N3 O4



CM 2

CRN 64-18-6  
CMF C H2 O2




RN 216149-96-1 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-88-8  
CMF C21 H29 N3 O4



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 216149-98-3 HCPLUS

CN Butanedioic acid, hydroxy-, compd. with 3,3,7-trimethyl-6-octenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-88-8  
CMF C21 H29 N3 O4



CM 2


CRN 6915-15-7  
CMF C4 H6 O5



RN 216149-99-4 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-88-8  
CMF C21 H29 N3 O4



CM 2


CRN 77-92-9  
CMF C6 H8 O7



RN 216150-01-5 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-88-8  
CMF C21 H29 N3 O4



CM 2


CRN 65-85-0  
CMF C7 H6 O2



RN 216150-02-6 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)


CM 1

CRN 216148-88-8  
CMF C21 H29 N3 O4



CM 2

CRN 69-72-7  
CMF C7 H6 O3




RN 216150-03-7 HCAPLUS  
CN L-Ascorbic acid, compd. with 3,3,7-trimethyl-6-octenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8

CMF C21 H29 N3 O4




CM 2

CRN 50-81-7


CMF C6 H8 O6

Absolute stereochemistry.



RN 216150-04-8 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216150-06-0 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216150-07-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216150-08-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-89-9

CMF C15 H17 N3 O4



CM 2


CRN 7697-37-2  
CMF H N O3



RN 216150-09-3 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, phosphate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-89-9  
CMF C15 H17 N3 O4



CM 2


CRN 7664-38-2  
CMF H3 O4 P



RN 216150-10-6 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9  
CMF C15 H17 N3 O4



CM 2

CRN 64-18-6  
CMF C H2 O2


O=CH-OH

RN 216150-12-8 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-89-9  
CMF C15 H17 N3 O4



CM 2

CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.




RN 216150-17-3 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-89-9  
CMF C15 H17 N3 O4



CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 216150-19-5 HCPLUS  
CN Butanedioic acid, hydroxy-, compd. with 1-cyclopropylethyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-89-9  
CMF C15 H17 N3 O4



CM 2

CRN 6915-15-7  
CMF C4 H6 O5




RN 216150-20-8 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-89-9

CMF C15 H17 N3 O4



CM 2


CRN 77-92-9  
CMF C6 H8 O7



RN 216150-21-9 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-89-9  
CMF C15 H17 N3 O4



CM 2


CRN 65-85-0  
CMF C7 H6 O2



RN 216150-22-0 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-cyclopropylethyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)


CM 1

CRN 216148-89-9  
CMF C15 H17 N3 O4



CM 2

CRN 69-72-7  
CMF C7 H6 O3




RN 216150-23-1 HCAPLUS

CN L-Ascorbic acid, compd. with 1-cyclopropylethyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 216148-89-9  
CMF C15 H17 N3 O4



CM 2

CRN 50-81-7  
CMF C6 H8 O6


Absolute stereochemistry.



Searched by: Mary Hale 571-272-2507 REM 1D86

RN 216150-27-5 HCPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-,  
2,4,4-trimethylpentyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216150-28-6 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-,  
2,4,4-trimethylpentyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216150-30-0 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-,  
2,4,4-trimethylpentyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216150-31-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 7697-37-2

CMF H N O3




RN 216150-32-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 216150-34-4 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 64-18-6

CMF C H2 O2




RN 216150-35-5 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2

CMF C18 H25 N3 O4




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.

Searched by: Mary Hale 571-272-2507 REM 1D86




RN 216150-40-2 HCAPLUS

CN Butanedioic acid, hydroxy-, compd. with 2,4,4-trimethylpentyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 216150-41-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-90-2

CMF C18 H25 N3 O4



CM 2


CRN 77-92-9  
CMF C6 H8 O7



RN 216150-42-4 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, monobenzoate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-90-2  
CMF C18 H25 N3 O4



CM 2


CRN 65-85-0  
CMF C7 H6 O2



RN 216150-43-5 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)


CM 1

CRN 216148-90-2  
CMF C18 H25 N3 O4



CM 2


CRN 69-72-7  
CMF C7 H6 O3



RN 216150-44-6 HCAPLUS  
CN L-Ascorbic acid, compd. with 2,4,4-trimethylpentyl 2-[ (methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-90-2  
CMF C18 H25 N3 O4



CM 2

CRN 50-81-7  
CMF C6 H8 O6


Absolute stereochemistry.



RN 216150-45-7 HCAPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[ (methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-90-2  
CMF C18 H25 N3 O4



CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 216150-46-8 HCPLUS  
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-88-8  
CMF C21 H29 N3 O4



CM 2

CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



=> s 13 and (pharmac? or compos?)  
L9 0 FILE MEDLINE

Searched by: Mary Hale 571-272-2507 REM 1D86

L10 3 FILE HCAPLUS  
L11 0 FILE BIOSIS  
L12 0 FILE EMBASE

TOTAL FOR ALL FILES

L13 3 L3 AND (PHARMAC? OR COMPOS?)

=> s l13 not 18  
L14 0 FILE MEDLINE  
L15 1 FILE HCAPLUS  
L16 0 FILE BIOSIS  
L17 0 FILE EMBASE

TOTAL FOR ALL FILES

L18 1 L13 NOT L8

=> d cbib abs hitstr

L18 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN  
1994:124172 Document No. 120:124172 Segregation of activity profile in  
benzimidazoles: effect of spacers at 5(6)-position of methyl  
benzimidazole-2-carbamates. Agarwal, Shiv K.; Sharma, Satyavan; Bhaduri,  
A. P. (Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, 226001, India).  
Zeitschrift fuer Naturforschung, C: Journal of Biosciences, 48(11-12),  
829-38 (English) 1993. CODEN: ZNCBDA. ISSN: 0341-0382.

AB The design and synthesis of a series of Me 5(6)-substituted  
benzimidazole-2-carbamates as potential anthelmintics are described. A  
rational anal. of the structural parameters which segregate the activity  
of resulting benzimidazole-2-carbamates against enteric and tissue  
dwelling helminths is presented. The influence of single and multiple  
spacers, which link the **pharmacophores** at 5(6)-position of  
benzimidazole-2-carbamate, on the activity against *Ancylostoma ceylanicum*  
(hookworm), *Syphacia obvelata* (pinworm), *Hymenolepis nana* (tapeworm)  
*Litomosoides carinii* and *Acanthocheilonema viteae* (filarial worm) has been  
presented. This anal. indicates that for activity against intestinal  
helminth the presence of one spacer holding the **pharmacophore**  
approx. 3 Å apart from the parent nucleus is usually preferred. While  
for activity against tissue dwelling parasite, the repetition of the  
benzimidazole-2-carbamate nucleus joined together through the  
5,5'-position with one spacer kept apart by distance of 3 Å unit is  
usually desired.



IT 121649-63-6 121649-65-8 121649-66-9  
153213-39-9 153213-40-2 153213-41-3  
153213-42-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)

(anthelmintic activity of, structure-activity relations in)

RN 121649-63-6 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, methyl  
ester (9CI) (CA INDEX NAME)



RN 121649-65-8 HCAPLUS


Searched by: Mary Hale 571-272-2507 REM 1D86

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, propyl ester (9CI) (CA INDEX NAME)




RN 121649-66-9 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 153213-39-9 HCPLUS

CN Carbamic acid, [5-[[4-(benzoyl-1-piperazinyl)oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 153213-40-2 HCPLUS

CN Carbamic acid, [5-[[4-(2-furanylcarbonyl)-1-piperazinyl]oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 153213-41-3 HCPLUS

CN Carbamic acid, [5-[[4-[(diethylamino)carbonyl]-1-piperazinyl]oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 153213-42-4 HCPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, phenyl ester (9CI) (CA INDEX NAME)



=> fil caol;s 13

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	58.82	216.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.54	-5.54

FILE 'CAOLD' ENTERED AT 09:16:56 ON 01 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L19 0 L3

=> fil med1,hcap1,biosis,embase,jisct,wpids;s agyin, j?/au,in or agyin j?/au,in;s quada, j?/au,in or quada j?/au,in  
 'JISCT' IS NOT A VALID FILE NAME  
 Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files

Searched by: Mary Hale 571-272-2507 REM 1D86

that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):jicst

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.68	217.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.54

FILE 'MEDLINE' ENTERED AT 09:19:10 ON 01 APR 2004

FILE 'HCAPLUS' ENTERED AT 09:19:10 ON 01 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:19:10 ON 01 APR 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 09:19:10 ON 01 APR 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 09:19:10 ON 01 APR 2004

COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'WPIDS' ENTERED AT 09:19:10 ON 01 APR 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

'IN' IS NOT A VALID FIELD CODE

L20 0 FILE MEDLINE

L21 15 FILE HCAPLUS

L22 11 FILE BIOSIS

'IN' IS NOT A VALID FIELD CODE

L23 2 FILE EMBASE

L24 0 FILE JICST-EPLUS

L25 8 FILE WPIDS

TOTAL FOR ALL FILES

L26 36 AGYIN, J?/AU, IN OR AGYIN J?/AU, IN

'IN' IS NOT A VALID FIELD CODE

L27 5 FILE MEDLINE

L28 19 FILE HCAPLUS

L29 18 FILE BIOSIS

'IN' IS NOT A VALID FIELD CODE

L30 7 FILE EMBASE

L31 0 FILE JICST-EPLUS

L32 6 FILE WPIDS

TOTAL FOR ALL FILES

L33 55 QUADA, J?/AU, IN OR QUADA J?/AU, IN

=> s camden, j?/au,in or camden j?/au,in

'IN' IS NOT A VALID FIELD CODE

L34 38 FILE MEDLINE

L35 93 FILE HCAPLUS

L36 111 FILE BIOSIS

Searched by: Mary Hale 571-272-2507 REM 1D86

'IN' IS NOT A VALID FIELD CODE  
L37 27 FILE EMBASE  
L38 0 FILE JICST-EPLUS  
L39 61 FILE WPIDS

TOTAL FOR ALL FILES  
L40 330 CAMDEN, J?/AU, IN OR CAMDEN J?/AU, IN

=> s 126 and 133 and 140  
L41 0 FILE MEDLINE  
L42 7 FILE HCAPLUS  
L43 8 FILE BIOSIS  
L44 0 FILE EMBASE  
L45 0 FILE JICST-EPLUS  
L46 6 FILE WPIDS

TOTAL FOR ALL FILES  
L47 21 L26 AND L33 AND L40

=> s 147 not (113 or 18)  
L48 0 FILE MEDLINE  
L49 2 FILE HCAPLUS  
L50 8 FILE BIOSIS  
L51 0 FILE EMBASE  
L52 0 FILE JICST-EPLUS

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=> fil hcaplu,biosis;s 149		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.76	229.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-5.54

FILE 'HCAPLUS' ENTERED AT 09:20:11 ON 01 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:20:11 ON 01 APR 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

L53 2 FILE HCAPLUS  
L54 8 FILE BIOSIS

TOTAL FOR ALL FILES  
L55 10 L49

=> dup rme 155  
ENTER REMOVE, IDENTIFY, ONLY, OR (?):end

=> dup rem 155  
PROCESSING COMPLETED FOR L55

Searched by: Mary Hale 571-272-2507 REM 1D86

=> d cbib abs 1-10

L56 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN  
2004:240413 Compounds and methods for use thereof in the treatment of cancer.

**Camden, James Berger**; Agyin, Joseph K.; Quada, James C., Jr. (UAF Technologies and Research, LLC, USA). U.S. US 6710065 B1 20040323, 19 pp., Cont.-in-part of U.S. 6,506,783. (English). CODEN: USXXAM.

APPLICATION: US 2000-676031 20000929. PRIORITY: US 1997-857811 19970516.

AB Benzimidazole derivs. and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compds. Such compds. may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 2 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

2003:435114 Document No.: PREV200300435114. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Camden, James Berger** [Inventor, Reprint Author]; **Quada, James C. Jr.** [Inventor]; **Agyin, Joseph K.** [Inventor]. ASSIGNEE: University of Arizona Foundation. Patent Info.: US 6608096 August 19, 2003. Official Gazette of the United States Patent and Trademark Office Patents, (Aug 19 2003) Vol. 1273, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

ISSN: 0098-1133 (ISSN print). Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm-blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:256239 Document No. 136:289365 Benzimidazole compounds and methods for use thereof in the treatment of cancer or viral infections. **Quada, James C., Jr.**; Agyin, Joseph K.; Camden, James Berger (Procter & Gamble Company, USA). PCT Int. Appl. WO 2002026716 A2 20020404, 42 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US29261 20010919. PRIORITY: US 2000-670169 20000926; US 2000-670168 20000926; US 2000-670170 20000926; US 2000-670166 20000926.

AB Benzimidazole derivs. and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compds. Such compds. may be used in combination with a chemotherapeutic agent and/or a potentiator. 2-Aminobenzimidazole was reacted with benzyl isocyanate to give a product that inhibited murine melanoma and human colon carcinoma with IC50s of 73.5 and 66.0  $\mu$ M, resp.

L56 ANSWER 4 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

2003:43719 Document No.: PREV20030043719. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Quada, James C. Jr.** [Inventor, Reprint Author]; **Agyin, Joseph K.** [Inventor]; **Camden, James Berger** [Inventor]. ASSIGNEE: The Procter & Gamble Company. Patent Info.: US 6482843 November 19, 2002. Official Gazette of the United States Patent and Trademark Office Patents,

(Nov 19 2002) Vol. 1264, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

ISSN: 0098-1133 (ISSN print). Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 5 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:476593 Document No.: PREV200200476593. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Camden, James Berger** [Inventor]; **Agyin, Joseph K.** [Inventor]; **Quada, James C., Jr.** [Inventor]. ASSIGNEE: The Proctor and Gamble Company. Patent Info.: US 6423736 July 23, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (July 23, 2002) Vol. 1260, No. 4. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 6 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:476592 Document No.: PREV200200476592. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Camden, James Berger** [Inventor]; **Quada, James C., Jr.** [Inventor]; **Agyin, Joseph K.** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6423735 July 23, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (July 23, 2002) Vol. 1260, No. 4. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 7 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:475376 Document No.: PREV200200475376. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Camden, James Berger** [Inventor]; **Agyin, Joseph K.** [Inventor]; **Quada, James C., Jr.** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6420411 July 16, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (July 16, 2002) Vol. 1260, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 8 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:412217 Document No.: PREV200200412217. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Quada, James C., Jr.** [Inventor]; **Agyin, Joseph K.** [Inventor]; **Camden, James Berger** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6407131 June 18, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (June 18, 2002) Vol. 1259, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 9 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:412194 Document No.: PREV200200412194. Compounds and methods for use thereof in the treatment of cancer or viral infections. **Quada, James C., Jr.** [Inventor]; **Agyin, Joseph K.** [Inventor]; **Camden, James Berger** [Inventor]. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6407105 June 18, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (June 18, 2002) Vol. 1259, No. 3. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

L56 ANSWER 10 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:315029 Document No.: PREV200200315029. Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof. **Quada, James C., Jr.** [Inventor, Reprint author]; **Agyin, Joseph K.** [Inventor]; **Camden, James Berger** [Inventor]. San Antonio, TX, USA. ASSIGNEE: The Procter and Gamble Company. Patent Info.: US 6380232 April 30, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 30, 2002) Vol. 1257, No. 5. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	27.75	257.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.39	-6.93

STN INTERNATIONAL LOGOFF AT 09:20:34 ON 01 APR 2004